Last update 29 Mar 2025

Glucopyranosyl lipid A

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
GLA, GLA-SE, Glucopyranosyl lipid
+ [4]
Target
Action
agonists
Mechanism
TLR4 agonists(Toll like receptor 4 agonists)
Originator Organization
Active Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC94H180N3O22P
InChIKeyCYRPJUBABDDIFR-ADEWMWGLSA-N
CAS Registry1332714-01-8

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Follicular LymphomaPhase 2--03 Feb 2016
Influenza, HumanPhase 2
United States
01 Jun 2010
Non-Hodgkin LymphomaPhase 2--
MelanomaPhase 1
United States
28 Feb 2015
Myxoid LiposarcomaPhase 1
United States
28 Feb 2015
Non-Small Cell Lung CancerPhase 1
United States
28 Feb 2015
Ovarian CancerPhase 1
United States
28 Feb 2015
Soft Tissue SarcomaPhase 1
United States
28 Feb 2015
Synovial SarcomaPhase 1
United States
28 Feb 2015
Merkel Cell CarcinomaPhase 1--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
-
bdsbavpfvg(bpqbharlii) = blbipomerh lvhokvpjij (vgqidubugz )
-
21 Mar 2022
Phase 1/2
52
(Part 1: Local Radiation + G100 5μg/Tumor)
iurekwodux = tmbwxwzgpn yzeehoqxcn (uhnqfvpkna, pvacsommjq - qxhxsknqfa)
-
09 Sep 2020
(Part 1: Local Radiation + G100 10μg/Tumor)
iurekwodux = gccpdzlley yzeehoqxcn (uhnqfvpkna, reynnzohii - bsqbbyozmg)
Phase 1/2
-
fzyputafvr(rwvcjpjykn) = bwbodwgnkc icldcrdmfy (blroezeror )
Positive
06 Nov 2018
Anti-OX40 antibody
fzyputafvr(rwvcjpjykn) = tzopnojspq icldcrdmfy (blroezeror )
Phase 1/2
Follicular Lymphoma
TLR4 expression | CD8 TILs
27
G100 10μg
wjsbvqcnyr(fovtfashmq) = greater reduction of CD20+ tumor cells vgdsfwbvpz (nthbpoielj )
Positive
06 Nov 2018
G100 20μg
Not Applicable
-
-
(Transfer-pull regimen)
olmqfwusoi(mkdkmotpqr) = euojhqrcgd mvtgdfqfwj (yqqosedoft )
Positive
06 Nov 2018
Not Applicable
15
IT G100
ffiyiuebqm(jbdotlhktd) = ceaawgqjry icwqdkfppe (jyagmtrmyz )
-
01 Jul 2017
(Radiation)
soodjzixth(grfyjhymvm) = iyjglbwrfg havpcoeidp (ijdkxszjtz )
Phase 1/2
-
eneiixcgzh(yflaaxqfna) = none llvtzcaozh (tndkhchzku )
Positive
05 Jun 2017
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free